Search results for: 'reagents for cell signaling'

This study provides insight into the challenges of current battery technology and their effects on electric vehicle adoption as original equipment manufacturers work to meet governmental emission mandates. Frost & Sullivan examines Tanktwo's game-changing battery technology that has the potential to alter the charging ecosystem altogether. The repo...

Immuno-oncology (I-O) therapies target tumors by harnessing the host s immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, includ...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

This study explores the global immuno-oncology (I-O) markets evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by Frost & Sullivan to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions. The study considers oncology agents for which the immune syst...

05 Aug 2024  |  Global  |  Technology Research

CGT Research Outlook and Technology Growth Opportunities

CGT Landscape Assessment

Infographics

×

The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, a...

There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases. Current study describes some of the recent advances in immunotherapy, mostly cancer. These include refined cell therapies, stem cell applications in cancer treatment, monoclonal, polyclonal and bispecific antibodies. Some of exci...

Over 21.6 million units of light-duty electric vehicles (EVs) were sold worldwide in 2025, representing a 23.5% year-over-year (YoY) growth. Battery electric vehicles (BEVs) accounted for 66.8% of all EVs sold, while plug-in hybrid electric vehicles (PHEVs) accounted for 33.2%. The PHEV share declined by 3% in 2025. The global EV penetration in the...

Companies that are investing in the renewable energy sector are looking for the energy type that will lead the 'Green Revolution'. This analysis will take an in-depth view into this issue and highlight how solar energy will compete in the global market. Several companies that participate in the semiconductor and surface mount technology equipment m...

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...